Ovarian Tissue Transplantation Using Autologous Platelet-Rich Plasma: A Pilot Clinical Trial

Area of Science:

• Reproductive Medicine
• Oncofertility
• Surgical Innovation

Background:

• Iatrogenic premature ovarian failure (POF) is a common consequence of oncologic treatments.
• Ovarian tissue cryopreservation and reimplantation offer fertility preservation but restoration of ovarian function can be challenging.
• Autologous platelet-rich plasma (PRP) has shown potential in regenerative medicine.

Purpose of the Study:

• To assess the feasibility and safety of using autologous PRP during laparoscopic orthotopic ovarian tissue reimplantation.
• To evaluate the impact of autologous PRP on the restoration of ovarian endocrine function.

Main Methods:

• A pilot prospective cohort study comparing 5 patients receiving PRP with 19 historical controls.
• Autologous PRP was prepared and used as a gel to cover cryopreserved ovarian tissue fragments.
• Laparoscopic orthotopic ovarian tissue reimplantation was performed, with data collected on adverse reactions, complications, and menstrual resumption.

Main Results:

• No intra- or postoperative complications or adverse reactions to PRP were observed.
• All patients receiving PRP demonstrated resumption of ovarian function.
• The time to first menses was significantly shorter in the PRP group (median 3 months) compared to the non-PRP group.

Conclusions:

• Autologous PRP is a feasible and safe adjunct for laparoscopic orthotopic ovarian tissue transplantation.
• PRP may enhance and accelerate the restoration of ovarian endocrine function after reimplantation.
• Further research is warranted to confirm these findings in larger cohorts.